National Energy Services Reunited Corp Ordinary Shares vs Novavax Inc — how do they compare? National Energy Services Reunited Corp Ordinary Shares trades at $18.94 (market cap $1.97B), while Novavax Inc trades at $12.39 (market cap $2.08B). The key difference: National Energy Services Reunited Corp Ordinary Shares and Novavax Inc are close in size by market cap, and Novavax Inc is trading nearer its 52-week high, National Energy Services Reunited Corp Ordinary Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold National Energy Services Reunited Corp Ordinary Shares for 0 Days and Novavax Inc for 59 Days on average.
| NESR | NVAX | |
|---|---|---|
Market Cap | $1.97B | $2.08B |
Volume | 4,629,858 | 8,501,139 |
Sector | Energy | Health |
52-Week High | $36.31 | $12.82 |
52-Week Low | $10.41 | $6.22 |
Typical Hold Time | 0 Days | 59 Days |
Enterprise Value | $2.10B | $1.66B |
Signals from Pluang's Aura AI — not financial advice
NESR trades at $21.03, up 0.62% today, with neutral technical signals and strong fundamental momentum. The company has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $0.44 exceeding expectations by 25%. Revenue growth remains robust, driven by Middle East operations including the Jafurah gas field expansion. Analyst sentiment is overwhelmingly positive with 83% buy ratings and a consensus price target of $41.80, representing nearly 100% upside potential.
The outlook remains favorable with projected revenue growth to $1.6B in 2026 and net profit doubling to $93M. Key risks include execution pressure from premium valuation and regional geopolitical uncertainties. The recent lithium extraction deal with Saudi Aramco provides additional growth optionality, though capital demands remain elevated. Current levels offer attractive entry for growth-oriented investors despite technical neutrality.
Novavax (NVAX) trades at $12.82, up 1.26% with a bullish technical outlook. The company reported strong revenue of $1.12B in 2025 and net income of $440.30M, marking a significant turnaround. Recent earnings beats and FDA approvals for updated COVID-19 vaccines support momentum. However, negative cash flow and high debt levels pose challenges.
The outlook is mixed: analyst consensus is 74% Buy with bullish technical signals, but profitability remains volatile. Key risks include cash burn and competitive pressure. Upside depends on successful Matrix-M platform adoption and partnership execution. Investors should weigh strong recent performance against fundamental weaknesses.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
National Energy Services Reunited Corp (NESR) is a Houston-based oilfield services company that provides drilling, evaluation, and production services, including hydraulic fracturing, cementing, coiled tubing, and directional drilling, to oil and gas operators. It focuses primarily on markets across the Middle East, North Africa, and Asia Pacific.
Read more on NESR →Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →